Myelodysplastic syndrome (MDS) is a group of blood cancers in which the bone marrow doesn't make enough healthy blood cells, leading to anemia, infection risk, and fatigue that can range from mild to severe. It's most often diagnosed in older adults — sometimes found through a routine blood test before symptoms even appear — and its course can be unpredictable: some people live for years with stable, low-risk disease, while others progress toward acute leukemia. A large national registry study set out to measure just how much the diagnosis itself affects mental health, not just quality of life on paper.
What Research Shows
Researchers followed 1,307 people with MDS (median age 75) in Denmark's national health registries and compared them with 6,535 people from the general population, matched 5:1 on age, sex, and country of origin. Within two years of diagnosis, 21.2% of MDS patients were prescribed a psychotropic drug — an antidepressant, anxiolytic, or antipsychotic — compared with just 7.9% of matched comparators, nearly three times the rate (hazard ratio 2.5). Looking at specific drug classes, anxiolytic use (11.9% vs 8.4%) and antipsychotic use (8.9% vs 6%) were both significantly elevated (p<0.001); antidepressant use was also somewhat higher (15.1% vs 13.1%), though that particular difference didn't reach statistical significance on its own. Because these figures track actual prescriptions rather than self-reported symptoms, they likely understate the true scale of emotional distress — not everyone who feels depressed or anxious seeks, or is offered, medication.
Ways to Cope
- Know that your risk of needing mental health support is real, not imagined. This research found MDS patients were prescribed psychiatric medication at nearly three times the rate of similar people without the disease — so if you're struggling emotionally, you're responding normally to a genuinely difficult diagnosis, not overreacting.
- Ask about your specific risk category. The same research found that people with higher-risk MDS (by IPSS-R score) were more likely to need psychotropic medication. Understanding where your disease falls on that spectrum can help you and your care team anticipate — rather than just react to — emotional strain.
- Bring up mood and anxiety at routine appointments, not just blood counts. Hematology visits often focus tightly on lab values. Proactively mentioning how you're coping emotionally gives your care team a chance to screen for depression or anxiety before things become a crisis.
- Pace around fatigue and infection-risk realities. Low blood counts can mean real physical limits on energy and immune function. Planning rest and limiting high-exposure situations isn't giving in to the disease — it's working with your actual capacity right now.
- Connect with others managing MDS specifically. MDS has a different course and outlook than more familiar cancers, and generic cancer-support spaces don't always address it well. Condition-specific patient communities can reduce the isolation of a diagnosis many people have never heard of.
Why the Real Number Is Likely Higher
This data comes from prescription records, not self-report symptom surveys, and that distinction matters. A 21.2% two-year rate of psychotropic prescriptions is a proxy for diagnosed, treated distress — not the full picture of how many people with MDS experience depression or anxiety at some point. Being prescribed medication requires bringing up symptoms, having a clinician recognize them, and choosing a pharmacological route — several steps where distress can go unspoken or unrecognized. The research also identified specific risk factors within the MDS population: older age, lower educational attainment, a higher burden of other health conditions (a Charlson Comorbidity Index score of 1 or more), and higher-risk disease by IPSS-R score were each linked to a greater likelihood of being prescribed psychotropic medication. None of this means distress is inevitable with MDS; it means the diagnosis carries a real, measurable mental-health toll that deserves the same attention as physical monitoring.
You're Not Alone
Because this research suggests MDS carries a real and elevated risk of anxiety and depression requiring treatment, our guide to Feeling Anxious or Stressed and our page on Feeling Low or Depressed may offer a starting point. And because living with MDS means navigating an unpredictable, often lifelong illness, our page on Living with Chronic Illness or Pain or our guide to Cancer Survivorship and Mental Health may offer additional support.
Tips for Supporting Someone With MDS
- Don't assume it's “just” a blood disorder. MDS is a form of blood cancer with a real risk of progressing to acute leukemia. Treating it as minor because it's unfamiliar can leave someone feeling unseen in a genuinely serious diagnosis.
- Take fatigue and infection precautions seriously. Low blood counts aren't just a lab number — they can mean real, fluctuating limits on energy and immune function that aren't visible from the outside.
- Ask how they're coping emotionally, not just about their latest blood test. This research found a meaningful share of people with MDS are prescribed medication for anxiety or depression — checking in on mood matters as much as checking in on counts.
- Understand the uncertainty they're living with. MDS can stay stable for years or progress unpredictably. Not having a clear timeline is its own source of stress, even when things currently look stable.
- Be patient if they don't want to discuss prognosis. Given how unpredictable the disease course can be, someone may prefer to focus on day-to-day life rather than long-term statistics — respect that pacing.